Figure 4
Micromolar affinity CAR T cells provide superior tumor eradication, suppression of tumor relapse, and survival benefit. (a) Whole-body luminescence imaging was used to estimate tumor burden in mice infused with different CAR T cell variants 8 days post-tumor implantation. No T = mice received no T cells. (b) Mice were treated with CAR T cells 10 days post tumor implantation. NT = non-transduced T cells. (c) Luminescence measurements of mice treated with different CAR T cells. Individual lines indicate luminescence values from each mouse. P values of two-tailed student’s t-test versus NT (n = 3) are not-significant for No T (n = 8), p < 0.001 for F292A (n = 8) and F292G (n = 5), and p < 0.05 for TM (n = 5). (d) Percentage body weight fluctuation from initial weight on day 0 post tumor xenografts of mice receiving different treatments are depicted. (e) Survival curves of mice receiving different treatments. Log-rank (Mantel-Cox) test P values versus NT are not-significant for No T and TM, and p = 0.008 for F292G, p = 0.025 for R6.5, and p = 0.0016 for F292A.
